BioCentury
ARTICLE | Clinical News

Xeljanz beats placebo in Phase III psoriatic arthritis trial

April 6, 2016 12:10 AM UTC

Pfizer Inc. (NYSE:PFE) said 5 and 10 mg twice-daily Xeljanz tofacitinib met the co-primary endpoints of superiority to placebo at three months in the Phase III OPAL Broaden trial to treat psoriatic arthritis. Efficacy was measured by the proportion of patients who achieved an ACR20 response and Health Assessment Questionnaire Disability Index (HAQ-DI) scores.

The trial also evaluated Humira adalimumab from AbbVie Inc. (NYSE:ABBV) every two weeks as an active control. Pfizer did not report Humira data from OPAL Broaden, and said the study was not powered to evaluate non-inferiority or superiority of Xeljanz vs. Humira. The pharma plans to present detailed OPAL Broaden data at a medical meeting. ...